Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:
Total revenue	$ 82,883	$ 67,192	$ 247,206	$ 214,755
Operating expenses:
Research and development	17,486	19,000	55,875	63,590
Sales and marketing	19,802	18,474	60,634	63,335
General and administrative	28,515	33,968	83,104	91,327
Restructuring costs	0	0	68	848
Total operating expenses	93,375	95,975	281,133	295,486
Loss from operations	(10,492)	(28,783)	(33,927)	(80,731)
Other income:
Interest income, net	3,001	3,171	8,712	8,708
Change in estimated fair value of common stock warrant liability	0	0	0	10
Other income (expense), net	283	2,047	(107)	(198)
Total other income	3,284	5,218	8,605	8,520
Loss before income taxes	(7,208)	(23,565)	(25,322)	(72,211)
Income tax (expense) benefit	(200)	80	(139)	24
Net loss	$ (7,408)	$ (23,485)	$ (25,461)	$ (72,187)
Net loss per share (Note 3):
Basic (in dollars per share)	$ (0.14)	$ (0.43)	$ (0.49)	$ (1.34)
Diluted (in dollars per share)	$ (0.14)	$ (0.43)	$ (0.49)	$ (1.34)
Weighted-average shares used to compute net loss per share:
Basic (in shares)	52,903,338	54,178,759	52,266,106	53,891,374
Diluted (in shares)	52,903,338	54,178,759	52,266,106	53,891,374
Testing services revenue
Revenue:
Total revenue	$ 60,807	$ 47,784	$ 185,562	$ 162,982
Operating expenses:
Cost of testing services, product, digital, and other	13,447	13,217	41,387	43,837
Product revenue
Revenue:
Total revenue	10,212	9,536	29,416	24,273
Operating expenses:
Cost of testing services, product, digital, and other	6,212	4,750	17,801	12,742
Patient and digital solutions revenue
Revenue:
Total revenue	11,864	9,872	32,228	27,500
Operating expenses:
Cost of testing services, product, digital, and other	$ 7,913	$ 6,566	$ 22,264	$ 19,807